Brief: FDA Advisory Committee Votes Favorably That The Data Support Arimoclomol As Effective Treatment For Patients With Niemann-Pick Disease Type C

Zevra Therapeutics

02/08/2024 23:11

Aug 2 (Reuters) - Zevra Therapeutics Inc  ZVRA.O :
    * FDA ADVISORY COMMITTEE VOTES FAVORABLY THAT THE DATA
SUPPORT
ARIMOCLOMOL AS EFFECTIVE TREATMENT FOR PATIENTS WITH
NIEMANN-PICK DISEASE TYPE C
    * ARIMOCLOMOL NDA HAS BEEN ASSIGNED A PRESCRIPTION DRUG USER
FEE
ACT ACTION DATE OF SEPT 21, 2024

Source text for Eikon:  ID:nGNX1qfTFh 
Further company coverage:  ZVRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))